07:00 , Apr 25, 2016 |  BC Week In Review  |  Company News

Cellect Biomed, Accellta deal

Cellect granted Accellta non-exclusive rights to evaluate apoptotic induction-based technology. Accellta will evaluate if the technology can grow its pluripotent stem cells “safely and in a shorter time.” Cellect will receive an upfront payment of...
07:00 , Sep 24, 2015 |  BC Innovations  |  Emerging Company Profile

Accelerating stem cells

Growing human pluripotent stem cells on adherent surfaces is inefficient, expensive and often doesn't yield homogeneous cell preparations. Accellta Ltd. has suspension-based, feeder-free methods that produce homogeneous pluripotent stem cells and differentiate them in sufficient...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Miltenyi Biotec, Alfred Mann Institute deal

The institute’s Accellta Ltd. subsidiary granted Miltenyi Biotec non-exclusive, worldwide rights to an Accellta patent for use in Miltenyi’s medium for stem cell cultivation. The partners could not be reached for details. Accellta said it...